Multiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird Bio ...

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

The deal comes after a challenging few years for 2seventy bio, which had divested research programmes in recent years.

BMS said it will release comprehensive data in a “future peer-reviewed setting.” “This is the first and only phase 3 study of a neoadjuvant-only immuno-oncology therapy to show a ...

Credit: JHVEPhoto / Shutterstock. US-based pharmaceutical company Bristol Myers Squibb (BMS) has reported results from the POETYK PSO long-term extension (LTE) trial of its drug candidate Sotyktu ...

POWELL — Outside of some stray pieces of crime scene tape around a Byron residence, there were few outward signs on Tuesday of the tragedy that had occurred the previous day. But people in the small ...

But so far, the company is striking out in its attempts to broaden its label. On Thursday, BMS revealed that a phase 3 trial of Opdualag as an adjuvant treatment for patients with completely ...

The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as large as its current approved indication, according to analysts. Bristol Myers ...

We saw more action on the M&A front this week as Novartis bought back its blood thinner abelacimab and the rest of Anthos Therapeutics for up to $3.1 billion and still ahead, a potential buyout of ...

A former BMS Re employee has filed a lawsuit in the New York Supreme Court, alleging that the company is preventing them from accepting positions at competitor Guy Carpenter by enforcing ...

Medium course (3–4 weeks) was considered as the optimal course. In addition, there were no differences between acupuncture and SATV (sham acupuncture therapy at verum points) on the same acupuncture ...